A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years

QR Code

A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years

Current standard of care (SoC) for the prevention of pneumococcal disease among Mexican adults aged ≥60 years is a sequential regimen of pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPSV23). This study estimated the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jose Luis Huerta, An Ta, Elizabeth Vinand, Gustavo Ivan Torres, Warisa Wannaadisai, Liping Huang
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Vaccine: X
Subjects:	Pneumococcal disease PCV20 Pneumococcal conjugate vaccine Adult Mexico National immunization program
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590136225000762
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
by: Masayoshi Shinjoh, et al.
Published: (2024-12-01)

Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review
by: Aiko Shono, et al.
Published: (2025-12-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024-12-01)

Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs
by: Johnna Perdrizet, et al.
Published: (2024-12-01)

Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review
by: Elmira Flem, et al.
Published: (2024-12-01)

A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics
by: Aurelija Petrutienė, et al.
Published: (2025-08-01)

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia
by: Vladislav V. Semerikov, et al.
Published: (2020-02-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

Immunological Efficacy and Safety of a New Pneumococcal Polysaccharide Conjugated Thirteen-Valent Vaccine in the Immunization of Adults and Children (Results of Clinical Studies in the Russian Federation)
by: I. V. Feldblium, et al.
Published: (2022-11-01)

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy
by: Mark A. Fletcher, et al.
Published: (2024-12-01)

Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review
by: Marcellin Mengouo Nimpa, et al.
Published: (2025-05-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013-01-01)

VACCINATION AGAINST PNEUMOCOCCAL INFECTIONS IN RUSSIAN FEDERATION: SOCIAL AND PHARMACOECONOMIC ASPECTS
by: A. V. Rudakova, et al.
Published: (2018-10-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Vaccinal Prevention of Pneumococcal Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

Analysis of Morbidity Dynamics and Factors Influencing the Development of Pneumococcal Infections among the Adult Population of the Sakha Republic (Yakutia)
by: A. N. Argunova, et al.
Published: (2018-09-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01)

Vaccination against Pneumococcal Infections of High-Risk People: Pharmacoeconomic Aspects
by: A. V. Rudakova, et al.
Published: (2020-01-01)

Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study
by: Haruka Maeda, et al.
Published: (2025-12-01)

Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression
by: I. A. Guchev
Published: (2020-05-01)

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
by: Ekaterina I. Alekseeva, et al.
Published: (2019-09-01)

Analysis of pneumococcal serotypes distribution to determine a model composition for a Russian pneumococcal conjugate vaccine
by: V. P. Trukhin, et al.
Published: (2022-07-01)

Effectiveness of pneumococcal conjugate 13-valent vaccine against severe pneumonia in Panama: a matched case-control study
by: Jacqueline Levy, et al.
Published: (2025-07-01)

Real-World Impact of Pneumococcal Conjugate Vaccines on Vaccine Serotypes and Potential Cross-Reacting Non-Vaccine Serotypes
by: Kevin Apodaca, et al.
Published: (2025-06-01)

Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study
by: M. Doyinsola Bailey, et al.
Published: (2025-12-01)

Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea
by: Young June Choe, et al.
Published: (2025-12-01)

Pneumococcal Infection and Vaccination-Related Knowledge, Attitudes and Practices Among Saudi Residents
by: Wed S. Althobaiti, et al.
Published: (2025-07-01)

Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study
by: Xiang Guo, et al.
Published: (2024-12-01)

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs
by: A. V. Rudakova, et al.
Published: (2019-12-01)

Preventive Efficacy of Pneumococcal Conjugated Vaccine (Population Aspects)
by: I. N. Protasova, et al.
Published: (2022-01-01)

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
by: A. V. Rudakova, et al.
Published: (2014-09-01)

The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy
by: Margarita A. Soloshenko, et al.
Published: (2017-10-01)